AstraZeneca’s COVID-19 vaccine was found to be only slightly less effective against the variant first found in India when compared to the strain identified in Kent, said the company’s Chief Executive Officer Pascal Soriot in an interview with Financial Times on Friday.
He added the company is in talks with governments, including the United Kingdom, about new contracts for booster doses.